- Home
- RMCO vs NNVC Comparison
RMCO vs NNVC Comparison
Compare RMCO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- NNVC
- Stock Information
- Founded
- RMCO 2021
- NNVC 2005
- Country
- RMCO United States
- NNVC United States
- Employees
- RMCO N/A
- NNVC N/A
- Industry
- RMCO Multi-Sector Companies
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- NNVC Health Care
- Exchange
- RMCO Nasdaq
- NNVC Nasdaq
- Market Cap
- RMCO 17.2M
- NNVC 17.7M
- IPO Year
- RMCO N/A
- NNVC N/A
- Fundamental
- Price
- RMCO $1.07
- NNVC $1.35
- Analyst Decision
- RMCO
- NNVC Strong Buy
- Analyst Count
- RMCO 0
- NNVC 1
- Target Price
- RMCO N/A
- NNVC $6.50
- AVG Volume (30 Days)
- RMCO 10.0K
- NNVC 130.2K
- Earning Date
- RMCO 11-22-2024
- NNVC 11-22-2024
- Dividend Yield
- RMCO N/A
- NNVC N/A
- EPS Growth
- RMCO N/A
- NNVC N/A
- EPS
- RMCO N/A
- NNVC N/A
- Revenue
- RMCO $644,293.00
- NNVC N/A
- Revenue This Year
- RMCO N/A
- NNVC N/A
- Revenue Next Year
- RMCO N/A
- NNVC N/A
- P/E Ratio
- RMCO N/A
- NNVC N/A
- Revenue Growth
- RMCO 126.99
- NNVC N/A
- 52 Week Low
- RMCO $0.70
- NNVC $1.00
- 52 Week High
- RMCO $5.90
- NNVC $3.59
- Technical
- Relative Strength Index (RSI)
- RMCO 53.62
- NNVC 42.61
- Support Level
- RMCO $1.04
- NNVC $1.44
- Resistance Level
- RMCO $1.19
- NNVC $1.58
- Average True Range (ATR)
- RMCO 0.08
- NNVC 0.08
- MACD
- RMCO 0.00
- NNVC -0.01
- Stochastic Oscillator
- RMCO 57.14
- NNVC 26.79
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.